Collagen type VI regulates TGFβ bioavailability in skeletal muscle

Area of Science:

• Muscle biology
• Extracellular matrix research
• Rare disease genetics

Background:

• Collagen VI-related disorders (COL6-RDs) are rare muscular dystrophies caused by mutations in COL6A1, COL6A2, or COL6A3 genes.
• Collagen type VI is crucial for skeletal muscle extracellular matrix (ECM) structure and function.
• The precise mechanism linking ECM defects to myofiber dysfunction in COL6-RDs remains unclear.

Purpose of the Study:

• To investigate the natural history and outcomes of COL6-RDs using a novel mouse model.
• To elucidate the mechanistic link between collagen VI deficiency and skeletal muscle dysfunction.
• To identify potential therapeutic targets for COL6-RDs.

Main Methods:

• Utilized a novel Col6a2-/- mouse model for COL6-RDs.
• Employed standardized Treat-NMD protocols for functional, histological, and physiological assessments.
• Analyzed the TGFβ pathway's role in disease pathogenesis.

Main Results:

• Demonstrated early dysregulation of the TGFβ pathway in the Col6a2-/- mouse model.
• Showcased the inability of the collagen VI-deficient matrix to regulate TGFβ bioavailability.
• Established a link between ECM abnormalities and downstream skeletal muscle pathology.

Conclusions:

• Propose a novel pathogenic mechanism for COL6-RDs involving ECM regulation of TGFβ.
• Suggest that targeting the TGFβ pathway could be a viable therapeutic strategy for COL6-RDs.
• Highlight the importance of the extracellular matrix in maintaining muscle health and function.